R&D channel feed – Endpoints News

R&D channel feed

Giving it a GO: Giant Roche selects a tiny player at LabCentral for its next cancer R&D partner

7 years ago

J&J shrugs off deals with Aduro that were worth up to $1.2B. Setback forces shift to Novartis alliance now

7 years ago

Merck’s cancer R&D juggernaut ties up to little Dragonfly’s natural born killer platform — with billions on the line

7 years ago

Loyola is working on a new and improved CAR-T product, looking to overcome high-frequency side effects

7 years ago

On the heels of a global R&D reorganization, Novo Nordisk outlines 250 US job cuts

7 years ago

Alnylam shoots for a speedy FDA OK after their next shot at fielding a pricey rare disease drug hits PhIII goal

7 years ago

J&J has decided — pharma giant dumps its development deal on Geron’s imetelstat, shattering shares

7 years ago

Eli Lilly picks up an oral GLP-1 diabetes drug from a big Roche sub for $50M in cash-plus deal — and it’s not a peptide

7 years ago

Aldeyra shares soar on positive PhII dry eye data — but lose some steam on second look

7 years ago

GSK's vaccine arm lays claim to a major breakthrough on tuberculosis

7 years ago

Roche's IMpower133 offers a glimpse at rare progress in fight against small cell lung cancer

7 years ago

Researchers point to R&D treaty to spur new infectious disease treatments

7 years ago

AstraZeneca spells out a major drop in the risk of death for stage 3 NSCLC patients taking Imfinzi — and why that's important

7 years ago

Cash-strapped Gemphire lets go of five staffers as it contends with a clinical hold

7 years ago

Chopping close to home, Novartis outlines plans to ax or move about 2,600 more jobs in another wave of global restructuring

7 years ago

Alexion’s Soliris wows in rare disease PhIII trial, opening up a new franchise worth $500M-$700M

7 years ago

Trailing rivals, AstraZeneca offers a hit and a miss on key cardio study for SGLT2 diabetes drug Farxiga

7 years ago

Amarin scores a big win for its cardio outcomes study on Vascepa — stock races higher as analysts applaud

7 years ago

Parker collaborator Tessa allies with St. Jude, launches a new T cell program for pediatric brain cancer

7 years ago

GTx execs' sole drug fails the lead indication study in a painful setback -- shares smashed

7 years ago

Dismissing critical reports on patient deaths, FDA says safety/effectiveness of Nuplazid holds up under review

7 years ago

A snapshot of upbeat PhII NASH data — from a very small trial — triggers a frenzy for Viking’s stock

7 years ago

United’s Martine Rothblatt endorses a biotech unicorn’s CEO and antes up for US rights to an IPF drug

7 years ago

Servier shrugs off a multimillion-dollar investment, abandoning a failed MS drug developed by GeNeuro

7 years ago

First page Previous page 264 265 266267268 269 270 Next page Last page